Sharon Lynch, MD
Neurology · Kansas City, KSNPI 1730288143
Payments from drug & device makers
Across 649 payments — averaging $14,328 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$5.5M
- Genentech, Inc.$1.2M
- Sanofi$537K
- F. Hoffmann-la Roche AG$442K
- Bristol Myers Squibb$305K
- TG Therapeutics, Inc.$288K
- plus $1.1M from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 32 | $5,472,139 |
| Genentech, Inc. | 92 | $1,187,428 |
| Sanofi | 75 | $537,343 |
| F. Hoffmann-la Roche AG | 110 | $442,148 |
| Bristol Myers Squibb | 40 | $305,404 |
| TG Therapeutics, Inc. | 34 | $288,443 |
| Hoffmann-la Roche Limited | 38 | $285,273 |
| Roche Products Limited | 53 | $253,104 |
| E.r. Squibb & Sons, L.L.C. | 11 | $133,042 |
| Adamas Pharmaceuticals, Inc. | 28 | $112,832 |
| AstraZeneca(2 entities) | 60 | $109,759 |
| Chugai Pharmaceutical Co., Ltd. | 21 | $79,493 |
| UCB SA | 15 | $30,896 |
| EMD Serono, Inc. | 6 | $21,612 |
| Amgen(2 entities) | 6 | $13,374 |
| Mallinckrodt Enterprises LLC | 7 | $10,992 |
| Janssen Research & Development, LLC | 4 | $8,414 |
| Mallinckrodt Hospital Products Inc. | 2 | $6,676 |
| Vanda Pharmaceuticals Inc. | 3 | $82 |
| Biogen | 5 | $78 |
| AbbVie(2 entities) | 2 | $36 |
| Banner Life Sciences, LLC | 2 | $35 |
| Invivyd Inc | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| CSL Behring | 1 | $15 |
How this compares
$9,298,658 in reported general payments places this provider in the 95th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Jeffrey BurnsKansas City$6.2M
- Rajesh PahwaKansas City$5M
- Mamatha PasnoorKansas City$3.9M
- Constantine FarmakidisKansas City$649K
- Richard DubinskyKansas City$261K
- Patrick LandazuriKansas City$256K
- Michael AbrahamKansas City$203K
- Omar JawdatKansas City$111K
- Amanda ThuringerKansas City$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.